Engineered immune cells take aim at Hard-to-Treat leukemia
NCT ID NCT07583303
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new personalized therapy called BSB-2002 for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells with a mutation in the NPM1 gene. The study will enroll 19 people to find the safest dose and see if the treatment can help control the leukemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BSB-2002 (personalized T-cell therapy) given with cyclophosphamide and fludarabine chemotherapy
- What this could lead to
- If successful, this could point toward a new treatment option for people with a specific type of AML that has returned or not responded to standard therapy.
- What could go wrong
- This is a very early (Phase 1) trial with only 19 participants, so safety and dosing are the main focus. It is not yet known if the therapy will effectively control the disease, and there are risks of side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- New hope for relapsed leukemia: targeted drug combo enters human trials